China Drug Price Negotiations: Another Race To The Bottom？

As China’s annual drug reimbursement talks kick into high gear and enter the final key stage before formal discussions, many will be watching for any signs of unusually aggressive price-cutting this year. Many fear another race to the bottom for pharma companies large or small, domestic or international.

This would be along the lines of what happened in 2021, during which the price of an innovative rare disease treatment was slashed by more than 95%, with a broader...